News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|June 13, 2024

Considerations for the Management of Pediatric Patients with Narcolepsy

Author(s)Karl Doghramji, MD, Chelsie Monroe, MSN, APN, PMHNP-BC

Focusing on the case of a 9-year-old with excessive daytime sleepiness and sudden episodes of muscle weakness, the panel discusses the difficulty in diagnosing pediatric patients with narcolepsy.

Episodes in this series

Video 1 - "Definition of Narcolepsy and Unmet Needs"

EP. 1 Definition of Narcolepsy and Unmet Needs

Video 2 - "Pathophysiology of Narcolepsy and the Role of Orexins"

EP. 2 Pathophysiology of Narcolepsy and the Role of Orexins

Video 2 - "Diagnostic Practices for Narcolepsy"

EP. 3 Diagnostic Practices for Narcolepsy

Video 2 - "Narcolepsy Evaluation, Management, and Treatment Considerations"

EP. 4 Narcolepsy Evaluation, Management, and Treatment Considerations

Video 5 - "Clinical Treatment Strategies for a Patient Suffering from EDS and Hypnagogic Hallucinations"

EP. 5 Clinical Treatment Strategies for a Patient Suffering from EDS and Hypnagogic Hallucinations

Video 6 - "Patient-Centered Approach: Adapting Narcolepsy Treatments to Address Adverse Events and Mitigate Misuse Risks"

EP. 6 Patient-Centered Approach: Adapting Narcolepsy Treatments to Address Adverse Events and Mitigate Misuse Risks

Video 7 - "Complex Case of a 23-Year-Old Male College Student Suffering From Narcolepsy Symptoms"

EP. 7 Complex Case of a 23-Year-Old Male College Student Suffering From Narcolepsy Symptoms

Video 8 - "Treatment Augmentation in a Patient with Narcolepsy and ADHD"

EP. 8 Treatment Augmentation in a Patient with Narcolepsy and ADHD

Chelsie Monroe, MSN, APN, PMHNP-BC, and Karl Doghramji, MD, FAASM, DFAPA

EP. 9 Considerations for the Management of Pediatric Patients with Narcolepsy

Chelsie Monroe, MSN, APN, PMHNP-BC, and Karl Doghramji, MD, FAASM, DFAPA

EP. 10 Non-Pharmacologic Interventions for Pediatric Patients with Narcolepsy

Chelsie Monroe, MSN, APN, PMHNP-BC, and Karl Doghramji, MD, FAASM, DFAPA

EP. 11 Clinical Pearls for the Management of Patients Suffering from Narcolepsy

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Andrey Popov/Adobe Stock

FDA Approves Oveporexton for Narcolepsy Type 1, First Drug to Treat Full Range of NT1 Symptoms

ByJessica Walters

August 5th 2026

TNX-102 SL in Major Depressive Disorder: Targeting Slow-Wave Sleep

TNX-102 SL in Major Depressive Disorder: Targeting Slow-Wave Sleep

ByGregory Sullivan, MD

July 29th 2026

Alzheimer

Targeting APOE4: A Promising Therapeutic Strategy for Alzheimer Disease

ByLeah Kuntz,Tri Doan, MD, PhD

July 20th 2026

cataplexy

FDA Accepts NDA for AXS-12 for the Treatment of Cataplexy in Narcolepsy

July 15th 2026

What Clinicians Might Miss in ADHD: Sleep Disorders, Comorbidities, and a Link to Depression

What Clinicians Might Miss in ADHD: Sleep Disorders, Comorbidities, and a Link to Depression

ByAnn Childress, MD

July 11th 2026

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Postpartum Psychosis on Trial: What the Lindsay Clancy Case Can Teach Us

Bringing Wearable Data Into Psychiatric Care: Amae Health Partners With Google Health Enterprise to Improve Outcomes

Centanafadine in ADHD: Clinical Significance of the First Triple Reuptake Inhibitor for ADHD

FDA Approves Oveporexton for Narcolepsy Type 1, First Drug to Treat Full Range of NT1 Symptoms

How Wearable Tech Can Translate Into Practical Precision Medicine in Psychiatry